UHS

Universal Health Services presents a compelling valuation anomaly within the healthcare facilities sector, trading at a TTM P/E of 6.78 despite delivering robust profitability metrics. The company's ROE of 21.02% substantially exceeds typical industry benchmarks, while the current price of $169.27 represents a 31% decline from its 52-week high of $246.32, creating a systematic screening opportunity for value-oriented strategies.

The acute care and behavioral health operator demonstrates fundamental strength across multiple dimensions. Revenue growth accelerated to 10.42% year-over-year, while EPS expanded at a 34.82% pace, suggesting operational leverage within the business model. The company's operating margin of 11.5% and net margin of 8.56% reflect disciplined cost management amid an inflationary healthcare environment. Balance sheet positioning remains adequate with a debt-to-equity ratio of 0.65 and current ratio of 1.05, providing financial flexibility for capital allocation decisions.

Systematic risk factors include the stock's beta of 1.15, indicating above-market volatility, and trading at 1.87 times book value while the price sits closer to the 52-week low. The market cap of $10.2B and P/S ratio of 0.58 position UHS at a significant discount to larger peers like HCA. The divergence between strong profitability metrics and compressed valuation multiples warrants examination of reimbursement trends, labor cost pressures, and behavioral health segment performance.

Relative to peers THC and EHC, the fundamental screener flags UHS's combination of high ROE and low P/E as statistically unusual, potentially reflecting sector-specific headwinds or company-specific concerns requiring deeper operational analysis.